ポスト

KEYNOTE-564 trial: Improved survival in renal-cell cancer after 1 year of adjuvant therapy was seen with pembrolizumab. At 4 years, 91% of pembrolizumab-treated patients were alive, as compared with 86% of those who received placebo after surgery. https://t.co/oVQXvyffL4

メニューを開く

NEJM@NEJM

人気ポスト

もっと見る
Yahoo!リアルタイム検索アプリ